FDA clears Caliway's CBL-514 combo with tirzepatide for Phase 2 trial as pivotal Phase 3 SUPREME-01 starts enrollment
Executive summary: Caliway received FDA IND clearance for its CBL-0201WR Phase 2 trial evaluating CBL-514 in combination with tirzepatide, and obtained U.S. IRB approval to start enrollment in the pivotal Phase 3 SUPREME-01 trial (CBL-0301). The clearance advances Caliway’s obesity/diabetes therapeutic candidate toward later-stage testing, potentially expanding treatment options in a market dominated by GLP-1 agonists.
Who is involved: Caliway (sponsor), the U.S. FDA (regulatory authority), and investigational sites overseeing the SUPREME-01 trial.
Likely next: The Phase 2 trial will commence dosing participants, while the Phase 3 trial continues enrollment; subsequent steps include interim efficacy readouts and potential FDA feedback before moving toward NDA submission.
Caliway has received FDA IND clearance for its CBL-0201WR Phase 2 trial, which will evaluate CBL-514 in combination with tirzepatide. In parallel, the pivotal Phase 3 SUPREME-01 trial (CBL-0301) has obtained U.S. IRB approval and begun enrollment. These steps move the candidate forward in the competitive obesity and diabetes treatment landscape, where combination approaches are increasingly explored to enhance efficacy beyond existing GLP-1 therapies.
Timeline
- — Caliway's CBL-514 Combination Therapy Cleared by U.S. FDA for Phase 2 Trial; Pivotal Phase 3 Trial SUPREME-01 Initiates Enrollment (PR Newswire)
Analysis — what this means
Likely next events
- Phase 2 trial CBL-0201WR to begin dosing participants
- Phase 3 trial SUPREME-01 to continue enrollment
Sectors affected
- Biotechnology
- Pharmaceuticals
- Diabetes and obesity therapeutics
Regulatory implications
- FDA IND clearance permits initiation of Phase 2 dosing
- IRB approval allows Phase 3 SUPREME-01 enrollment to proceed
- Future NDA submission will require demonstration of safety and efficacy from both phases
Historical parallels
- Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes (August 25 2026)
Key entities
Sources
Related cases
- Karmanos Cancer Institute begins offering the newly FDA‑approved KRAS G12C inhibitor daraxonrasib (Rasonque) for metastatic pancreatic cancer, marking the first clinical rollout of a targeted therapy for a historically hard‑to‑treat malignancy
- FDA’s approval of IMAAVY provides the first-ever drug for warm autoimmune hemolytic anemia, creating a new niche in rare disease therapeutics
- FDA approves Implantica's RefluxStop, clearing the way for US market entry of a new GERD treatment device
- FDA approval clears the way for Implantica’s RefluxStop to enter the U.S. GERD treatment market
- AbelZeta regains global rights to C‑CAR039 (Prizlon‑cel) and secures FDA IND clearance for large B‑cell lymphoma therapy
- Neuralytix launches full commercial availability of iD3 System for intraoperative nerve assessment in spine surgery, advancing real-time surgical safety technology